We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$6.76B
AUM Growth
-$342M
Cap. Flow
-$367M
Cap. Flow %
-5.43%
Top 10 Hldgs %
43.88%
Holding
93
New
7
Increased
14
Reduced
55
Closed
7
Avg Time Held
1.5 years
Top 10 Avg Time Held
1.8 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
VERV icon
Verve Therapeutics
VERV
+$80.4M
2
ZY
Zymergen Inc. Common Stock
ZY
+$60.1M
3
SKIN icon
SkinHealth Systems
SKIN
+$59.8M
4
ONEM
1Life Healthcare
ONEM
+$41.7M
5
LFST icon
Lifestance Health
LFST
+$33.2M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$116M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$96.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$85.8M
4
BIIB icon
Biogen
BIIB
+$45.6M
5
BEAM icon
Beam Therapeutics
BEAM
+$38.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
2 Consumer Staples 1.58%
3 Financials 0.69%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AYLA
76
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$6.8M 0.1%
667,816
– –
2020 Q2
4 quarters
STIM icon
77
Neuronetics
STIM
$149M
$6.32M 0.09%
394,355
-105,645
-21% -$1.46M
2021 Q1
1 quarter
CABA icon
78
Cabaletta Bio
CABA
$263M
$5.99M 0.09%
696,378
– –
2019 Q4
6 quarters
XERS icon
79
Xeris Biopharma Holdings
XERS
$1.84B
$5.53M 0.08%
1,358,825
-353,479
-21% -$1.35M
2018 Q2
12 quarters
AVIR icon
80
Atea Pharmaceuticals
AVIR
$363M
$5.1M 0.08%
237,360
-920,722
-80% -$27.7M
2020 Q4
2 quarters
TLIS icon
81
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$4.01M 0.06%
24,257
-2,410
-9% -$409K
2021 Q1
1 quarter
APRE icon
82
Aprea Therapeutics
APRE
$7.78M
$3.39M 0.05%
34,746
– –
2019 Q4
6 quarters
KA icon
83
DELISTED
Kineta, Inc. Common Stock
KA
$693K 0.01%
8,498
-78,788
-90% -$8.51M
2020 Q4
2 quarters
TCDA
84
DELISTED
Tricida, Inc. Common Stock
TCDA
$237K ﹤0.01%
54,758
– –
2018 Q2
12 quarters
SYRS icon
85
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$212K ﹤0.01%
3,891
-17,338
-82% -$1.03M
2016 Q2
20 quarters
OVID icon
86
Ovid Therapeutics
OVID
$441M
$159K ﹤0.01%
40,674
-81,276
-67% -$321K
2017 Q2
16 quarters
BIIB icon
87
Biogen
BIIB
$34.8B
– –
-162,847
Closed -$45.6M –
DVAX icon
88
DELISTED
Dynavax Technologies
DVAX
– –
-882,814
Closed -$8.68M –
MDT icon
89
Medtronic
MDT
$122B
– –
-979,108
Closed -$116M –
QURE icon
90
uniQure
QURE
$1.56B
– –
-284,160
Closed -$9.57M –
WVE icon
91
Wave Life Sciences
WVE
$629M
– –
-79,018
Closed -$443K –
CSLT
92
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-10,229
Closed -$15K –
GNMK
93
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-3,589,342
Closed -$85.8M –
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2021 Portfolio in Review

As of Q2 2021, Redmile Group held 93 positions worth $6.76B, down 4.8% from $7.1B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group withdrew a net $367M in Q2 2021, closing 7 positions and reducing 55 holdings. Its most notable exit was Medtronic, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Redmile Group opened a new position in Verve Therapeutics worth $117M.

  • Redmile Group's largest Q2 2021 buy was Verve Therapeutics: 1,936,530 shares worth $117M.
  • Redmile Group added most to SkinHealth Systems in Q2 2021, an estimated $59.8M increase.
  • Redmile Group's biggest Q2 2021 reduction was Zentalis Pharmaceuticals, cutting an estimated $96.2M.
  • Redmile Group fully exited Medtronic in Q2 2021, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 44% of its $6.76B portfolio in Q2 2021.
  • Redmile Group opened 7 new positions and closed 7 in Q2 2021.
  • Redmile Group's portfolio value fell 4.8% quarter-over-quarter to $6.76B.

Based on Redmile Group's 13F filing for Q2 2021, filed 16 Aug 2021.